Effects of Triflusal and Clopidogrel on the Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose To compare the efficacy and safety of antiplatelet agents for the secondary prevention of ischemic stroke based on cytochrome P450 2C19 (CYP2C19) polymorphisms. Methods This study was a prospective, multicenter, randomized, parallel-group, open-label, blind genotype trial. First time non-cardiogenic ischemic stroke patients were enrolled and screened within 30 days. Participants were randomized to receive either triflusal or clopidogrel for secondary stroke prevention. The primary outcome was the time from randomization to first recurrent ischemic stroke or hemorrhagic stroke. Results The required sample size was 1,080 but only 784 (73%) participants were recruited. In patients with a poor CYP2C19 genotype for clopidogrel metabolism (n=484), the risk of recurrent stroke among those who received triflusal treatment was 2.9% per year, which was not significantly different from those who received clopidogrel treatment (2.2% per year; hazard ratio[HR], 1.23; 95% confidence interval [CI], 0.60–2.53). In the clopidogrel treatment group (n=393), 38% had good genotypes and 62% poor genotypes for clopidogrel metabolism. The risk of recurrent stroke in patients with a good CYP2C19 genotype was 1.6% per year, which was not significantly different from those with a poor genotype (2.2% per year; HR, 0.69; 95% CI, 0.26–1.79). Conclusions Whilst there were no significant differences between the treatment groups in the rates of stroke recurrence, major vascular events, or coronary revascularization, the efficacy of antiplatelet agents for the secondary prevention of stroke according to CYP2C19 genotype status remains unclear.
Abstract
Background and Purpose To compare the efficacy and safety of antiplatelet agents for the secondary prevention of ischemic stroke based on cytochrome P450 2C19 (CYP2C19) polymorphisms. Methods This study was a prospective, multicenter, randomized, parallel-group, open-label, blind genotype trial. First time non-cardiogenic ischemic stroke patients were enrolled and screened within 30 days. Participants were randomized to receive either triflusal or clopidogrel for secondary stroke prevention. The primary outcome was the time from randomization to first recurrent ischemic stroke or hemorrhagic stroke. Results The required sample size was 1,080 but only 784 (73%) participants were recruited. In patients with a poor CYP2C19 genotype for clopidogrel metabolism (n=484), the risk of recurrent stroke among those who received triflusal treatment was 2.9% per year, which was not significantly different from those who received clopidogrel treatment (2.2% per year; hazard ratio[HR], 1.23; 95% confidence interval [CI], 0.60–2.53). In the clopidogrel treatment group (n=393), 38% had good genotypes and 62% poor genotypes for clopidogrel metabolism. The risk of recurrent stroke in patients with a good CYP2C19 genotype was 1.6% per year, which was not significantly different from those with a poor genotype (2.2% per year; HR, 0.69; 95% CI, 0.26–1.79). Conclusions Whilst there were no significant differences between the treatment groups in the rates of stroke recurrence, major vascular events, or coronary revascularization, the efficacy of antiplatelet agents for the secondary prevention of stroke according to CYP2C19 genotype status remains unclear.
참고문헌 (27)
- Warden BA, "Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke", Nat Rev Neurol, 8, pp.223~235 (2012)
- Kral M, "Oral antiplatelet therapy in stroke prevention. Minireview", Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 154, pp.203~210 (2010)
- Alexandrov AV, "Stroke and atherothrombosis: an update on the role of antiplatelet therapy", Int J Stroke, 3, pp.175~181 (2008)
- Siller-Matula JM, "Response variability to P2Y12 receptor inhibitors:expectations and reality", JACC Cardiovasc Interv, 6, pp.1111~1128 (2013)
- Zanger UM, "Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation", Pharmacol Ther, 138, pp.103~141 (2013)
- Alvarez-Sabin J, "Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up", Cerebrovasc Dis, 37, pp.181~187 (2014)
- Culebras A, "Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study", Neurology, 62, pp.1073~1080 (2004)
- Han SW, "Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): a multicenter, randomized, open-label, parallel-group trial", Int J Stroke, 11, pp.485~491 (2016)
- Mao L, "Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects", Arch Cardiovasc Dis, 106, pp.517~527 (2013)
- Matias-Guiu J, "Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction:the TACIP study: a randomized, double-blind, multicenter trial", Stroke, 34, pp.840~848 (2003)
- Sacco RL, "Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke", N Engl J Med, 359, pp.1238~1251 (2008)
- Mega JL, "Cytochrome p-450 polymorphisms and response to clopidogrel", N Engl J Med, 360, pp.354~362 (2009)
- Jun-Beom Lee, "Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease", Yonsei Medical Journal, 52(5), pp.734~738 (2011), 연세대학교의과대학
- Pan Y, "Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis", Circulation, 135, pp.21~33 (2017)
- McDonough CW, "CYP2C19 metabolizer status and clopidogrel efficacy in the secondary prevention of small subcortical strokes (SPS3) study", J Am Heart Assoc, 4, pp.e001652~ (2015)
- Wang Y, "Clopidogrel with aspirin in acute minor stroke or transient ischemic attack", N Engl J Med, 369, pp.11~19 (2013)
- Wang Y, "Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack", JAMA, 316, pp.70~78 (2016)
- Hong KS, "Recurrent ischemic lesions after acute atherothrombotic stroke: clopidogrel plus aspirin versus aspirin alone", Stroke, 47, pp.2323~2330 (2016)
- SPS3 Investigators, "Effects of clopidogrel added to aspirin in patients with recent lacunar stroke", N Engl J Med, 367, pp.817~825 (2012)
- Bauer T, "Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis", BMJ, 343, pp.d4588~ (2011)
- Paré G, "Effects of CYP2C19 genotype on outcomes of clopidogrel treatment", N Engl J Med, 363, pp.1704~1714 (2010)
- Doll JA, "Impact of CYP2C19 metabolizer status on patients with acs treated with prasugrel versus clopidogrel", J Am Coll Cardiol, 67, pp.936~947 (2016)
- Jochmann N, "Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases", Eur Heart J, 26, pp.1585~1595 (2005)
- Zaccardi F, "Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials", Atherosclerosis, 240, pp.439~445 (2015)
- Bo Norrving, "Evolving Concept of Small Vessel Disease through Advanced Brain Imaging", 대한뇌졸중학회지, 17(2), pp.94~100 (2015), 대한뇌졸중학회
- Chan A, "Pharmacogenomics in neurology: current state and future steps", Ann Neurol, 70, pp.684~697 (2011)
- Falcone GJ, "Current concepts and clinical applications of stroke genetics", Lancet Neurol, 13, pp.405~418 (2014)